484 related articles for article (PubMed ID: 20044843)
1. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
2. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
10. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
12. A cost-benefit analysis of RSV prophylaxis in high-risk infants.
Schrand LM; Elliott JM; Ross MB; Bell EF; Mutnick AH
Ann Pharmacother; 2001 Oct; 35(10):1186-93. PubMed ID: 11675842
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
Ohler KH; Pham JT
Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
18. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A
Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858
[TBL] [Abstract][Full Text] [Related]
19. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.
Chang RK; Chen AY
Pediatr Cardiol; 2010 Jan; 31(1):90-5. PubMed ID: 19915892
[TBL] [Abstract][Full Text] [Related]
20. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]